The frequency of a terminal effector CD8+ T cell subset, characterized as CD57+CXCR3+CCR7−CD45RA+, was increased in AML compared to MDS, a finding that was further confirmed by flow cytometry in a secondary cohort of patients. This evidence concerns the gene CD8A and acute myeloid leukemia.